AR030039A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES A SELECTIVE INHIBITOR DRUG OF CYCLOOXYGENASA-2, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT OR PREVENT AFFECTIONS THROUGH CYCLOOXYGENASE-2 AND METHOD TO MAKE SUCH MEDICINAL PRODUCT - Google Patents
PHARMACEUTICAL COMPOSITION THAT INCLUDES A SELECTIVE INHIBITOR DRUG OF CYCLOOXYGENASA-2, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT OR PREVENT AFFECTIONS THROUGH CYCLOOXYGENASE-2 AND METHOD TO MAKE SUCH MEDICINAL PRODUCTInfo
- Publication number
- AR030039A1 AR030039A1 ARP000106475A ARP000106475A AR030039A1 AR 030039 A1 AR030039 A1 AR 030039A1 AR P000106475 A ARP000106475 A AR P000106475A AR P000106475 A ARP000106475 A AR P000106475A AR 030039 A1 AR030039 A1 AR 030039A1
- Authority
- AR
- Argentina
- Prior art keywords
- cyclooxygenase
- medicinal product
- drug
- manufacture
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
Abstract
Composicion farmacéutica que comprende una o más unidades de dosificacion de administracion oral, cada una de las cuales comprende una droga inhibidora selectiva de la ciclooxigenasa-2 de baja solubilidad en agua en una cantidad terapéuticamente efectiva, donde la droga está presente en partículas solidas que tienen un tamano promedio de partícula de 500 nm a 900 nm y donde la droga inhibidora selectiva de la ciclooxigenasa-2 es un compuesto de formula (1) donde: R3 es un grupo metilo o amino; R4 es hidrogeno o un grupo alquilo C1-4 o alcoxilo; X es N o CR5, donde R5 es hidrogeno o halogeno; e Y y Z son independientemente átomos de carbono o de nitrogeno que definen con los átomos adyacentes un anillo de 5 a 6 miembros que no está sustituido o que está sustituido en una o más posiciones con grupos oxo, halo, metilo o halometilo. El uso de dicha composicion en la fabricacion de un medicamento para tratar oralmente de una a seis veces por día mediante una o más unidades de dosificacion, una condicion o una afeccion médica en un sujeto para la cual está indicado el tratamiento con un inhibidor de la ciclooxigenasa-2 y el método para obtener dicho medicamento.Pharmaceutical composition comprising one or more orally administered dosage units, each of which comprises a selective inhibitor drug of low water solubility cyclooxygenase-2 in a therapeutically effective amount, where the drug is present in solid particles having an average particle size of 500 nm to 900 nm and where the selective cyclooxygenase-2 inhibitor drug is a compound of formula (1) where: R3 is a methyl or amino group; R4 is hydrogen or a C1-4 alkyl or alkoxy group; X is N or CR5, where R5 is hydrogen or halogen; and Y and Z are independently carbon or nitrogen atoms that define with the adjacent atoms a 5- to 6-membered ring that is unsubstituted or that is substituted in one or more positions with oxo, halo, methyl or halomethyl groups. The use of said composition in the manufacture of a medicament to treat orally one to six times per day by means of one or more dosage units, a condition or a medical condition in a subject for which treatment with a drug inhibitor is indicated. cyclooxygenase-2 and the method to obtain said medication.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16985699P | 1999-12-08 | 1999-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR030039A1 true AR030039A1 (en) | 2003-08-13 |
Family
ID=22617480
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000106473A AR027897A1 (en) | 1999-12-08 | 2000-12-05 | FORM OF CELECOXIB IN SOLID STATE THAT EXHIBIT INCREASED BIODISPONIBILITY |
ARP000106475A AR030039A1 (en) | 1999-12-08 | 2000-12-06 | PHARMACEUTICAL COMPOSITION THAT INCLUDES A SELECTIVE INHIBITOR DRUG OF CYCLOOXYGENASA-2, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT OR PREVENT AFFECTIONS THROUGH CYCLOOXYGENASE-2 AND METHOD TO MAKE SUCH MEDICINAL PRODUCT |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000106473A AR027897A1 (en) | 1999-12-08 | 2000-12-05 | FORM OF CELECOXIB IN SOLID STATE THAT EXHIBIT INCREASED BIODISPONIBILITY |
Country Status (21)
Country | Link |
---|---|
KR (1) | KR100717570B1 (en) |
CN (1) | CN1216869C (en) |
AR (2) | AR027897A1 (en) |
AU (1) | AU2041201A (en) |
BG (1) | BG65239B1 (en) |
CO (1) | CO5251445A1 (en) |
CZ (1) | CZ20012875A3 (en) |
EA (1) | EA200401397A1 (en) |
EC (1) | ECSP003807A (en) |
ES (1) | ES2236011T3 (en) |
HU (1) | HUP0200580A3 (en) |
MY (2) | MY128971A (en) |
NZ (1) | NZ529933A (en) |
OA (1) | OA11831A (en) |
PE (1) | PE20010911A1 (en) |
PT (2) | PT1150960E (en) |
SV (1) | SV2002000235A (en) |
TW (1) | TWI276435B (en) |
WO (1) | WO2001041536A2 (en) |
YU (1) | YU57801A (en) |
ZA (2) | ZA200107146B (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ524252A (en) * | 2000-07-20 | 2004-03-26 | Lauras As | Cox-2 inhibitors for treating HIV and AIDS |
JP2004534812A (en) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | Pharmaceutical composition of dispersion of drug and neutral polymer |
WO2004061433A1 (en) * | 2002-12-30 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7078526B2 (en) | 2002-05-31 | 2006-07-18 | Transform Pharmaceuticals, Inc. | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
WO2004026235A2 (en) * | 2002-09-20 | 2004-04-01 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
US7446107B2 (en) | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
CA2477923C (en) | 2002-03-01 | 2021-02-23 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
JP2006511499A (en) * | 2002-05-13 | 2006-04-06 | ファルマシア コーポレイション | Stable amorphous celecoxib composite and its preparation |
MXPA05000232A (en) * | 2002-06-21 | 2005-06-17 | Transform Pharmaceuticals Inc | Pharmaceutical compositions with improved dissolution. |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
CA2511881C (en) * | 2002-12-30 | 2013-06-25 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a sodium salt of celecoxib with improved dissolution |
EA014443B1 (en) * | 2004-06-29 | 2010-12-30 | Никомед Данмарк Апс | Pharmaceutical composition (variants) and method for manufacturing thereof |
GB0423103D0 (en) * | 2004-10-19 | 2004-11-17 | Boots Healthcare Int Ltd | Therapeutic agents |
EP1865951A1 (en) * | 2005-03-14 | 2007-12-19 | Nycomed GmbH | Method for preventing cardiovascular diseases |
CN103462920A (en) * | 2012-06-06 | 2013-12-25 | 南京亿华药业有限公司 | Oral cyclo-oxygenase-2 inhibitor Celecoxib composition |
CN103524416B (en) * | 2013-10-29 | 2016-08-17 | 湖北华世通生物医药科技有限公司 | A kind of Novel celecoxib crystal form A and preparation method thereof |
CN103508958A (en) * | 2013-10-30 | 2014-01-15 | 中美华世通生物医药科技(武汉)有限公司 | Novel celecoxib crystal form C and preparation method thereof |
CN103539739B (en) * | 2013-10-30 | 2016-02-10 | 中美华世通生物医药科技(武汉)有限公司 | A kind of Novel celecoxib crystal form B and preparation method thereof |
KR101476096B1 (en) * | 2014-03-28 | 2014-12-24 | 대원제약주식회사 | Pharmaceutical composition comprising celecoxib with improved solubility |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
DK0924201T3 (en) * | 1993-11-30 | 2002-05-21 | Searle & Co | Tricyclic substituted pyrazolylbenzenesulfonamides and their use as cyclooxygenase II inhibitors |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
CN1107058C (en) * | 1995-02-13 | 2003-04-30 | G·D·瑟尔公司 | Substituted isoxazoles for the treatment of inflammation |
US5756529A (en) * | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
US5981576A (en) * | 1995-10-13 | 1999-11-09 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
EP0863134A1 (en) * | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2 |
AU3762699A (en) * | 1998-04-27 | 1999-11-16 | Pacific Northwest Cancer Foundation | (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
-
2000
- 2000-12-01 OA OA1200100210A patent/OA11831A/en unknown
- 2000-12-01 NZ NZ529933A patent/NZ529933A/en unknown
- 2000-12-01 ES ES00983865T patent/ES2236011T3/en not_active Expired - Lifetime
- 2000-12-01 CZ CZ20012875A patent/CZ20012875A3/en unknown
- 2000-12-01 CN CN008060835A patent/CN1216869C/en not_active Expired - Fee Related
- 2000-12-01 PT PT00983865T patent/PT1150960E/en unknown
- 2000-12-01 YU YU57801A patent/YU57801A/en unknown
- 2000-12-01 HU HU0200580A patent/HUP0200580A3/en unknown
- 2000-12-04 EC EC2000003807A patent/ECSP003807A/en unknown
- 2000-12-04 AU AU20412/01A patent/AU2041201A/en not_active Withdrawn
- 2000-12-04 WO PCT/US2000/030180 patent/WO2001041536A2/en not_active Application Discontinuation
- 2000-12-05 AR ARP000106473A patent/AR027897A1/en unknown
- 2000-12-06 EA EA200401397A patent/EA200401397A1/en unknown
- 2000-12-06 PE PE2000001299A patent/PE20010911A1/en not_active Application Discontinuation
- 2000-12-06 AR ARP000106475A patent/AR030039A1/en unknown
- 2000-12-06 PT PT00982255T patent/PT1150959E/en unknown
- 2000-12-06 KR KR1020017010017A patent/KR100717570B1/en not_active IP Right Cessation
- 2000-12-06 MY MYPI20005730A patent/MY128971A/en unknown
- 2000-12-06 MY MYPI20005733A patent/MY128366A/en unknown
- 2000-12-08 SV SV2000000235A patent/SV2002000235A/en not_active Application Discontinuation
- 2000-12-11 CO CO00094077A patent/CO5251445A1/en not_active Application Discontinuation
-
2001
- 2001-05-18 TW TW089125991A patent/TWI276435B/en not_active IP Right Cessation
- 2001-08-09 BG BG105808A patent/BG65239B1/en unknown
- 2001-08-29 ZA ZA200107146A patent/ZA200107146B/en unknown
- 2001-08-29 ZA ZA200107149A patent/ZA200107149B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200107149B (en) | 2003-02-28 |
HUP0200580A2 (en) | 2002-11-28 |
NZ529933A (en) | 2005-06-24 |
HUP0200580A3 (en) | 2002-12-28 |
KR100717570B1 (en) | 2007-05-15 |
ES2236011T3 (en) | 2005-07-16 |
MY128971A (en) | 2007-03-30 |
ZA200107146B (en) | 2002-08-29 |
OA11831A (en) | 2005-08-23 |
MY128366A (en) | 2007-01-31 |
CZ20012875A3 (en) | 2002-02-13 |
EA200401397A1 (en) | 2005-08-25 |
ECSP003807A (en) | 2005-07-06 |
PT1150959E (en) | 2008-04-21 |
KR20020002386A (en) | 2002-01-09 |
CN1216869C (en) | 2005-08-31 |
BG105808A (en) | 2002-09-30 |
PT1150960E (en) | 2005-06-30 |
SV2002000235A (en) | 2002-06-13 |
AU2041201A (en) | 2001-06-18 |
AR027897A1 (en) | 2003-04-16 |
TWI276435B (en) | 2007-03-21 |
YU57801A (en) | 2005-07-19 |
WO2001041536A2 (en) | 2001-06-14 |
CN1411447A (en) | 2003-04-16 |
BG65239B1 (en) | 2007-09-28 |
CO5251445A1 (en) | 2003-02-28 |
PE20010911A1 (en) | 2001-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR030039A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A SELECTIVE INHIBITOR DRUG OF CYCLOOXYGENASA-2, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT OR PREVENT AFFECTIONS THROUGH CYCLOOXYGENASE-2 AND METHOD TO MAKE SUCH MEDICINAL PRODUCT | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
CY1111088T1 (en) | PHARMACEUTICAL FORM FOR TOLTERODIN ADMINISTRATION WITH CONTROLLED LIBERTY | |
CR8352A (en) | PHARMACEUTICAL FORMULATIONS, PROCEDURES AND DOSAGE GUIDELINES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES | |
AR039744A1 (en) | METHODS AND DOSAGE FORMS TO INCREASE THE SOLUBILITY OF PHARMACOS COMPOSITIONS FOR CONTROLLED ADMINISTRATION | |
ES2170069T3 (en) | 1-ALFA-HYDROXIPREVITAMINE D FOR ORAL ADMINISTRATION. | |
BRPI0518266A2 (en) | modified-release oral medicinal product of at least one active ingredient in multi-capsule form | |
AR037517A1 (en) | DERIVATIVES OF NAFTIRIDINES, A PROCESS FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF AN INFLAMMATORY DISEASE | |
NO863620D0 (en) | PROCEDURE FOR PREPARING A PHARMACEUTICAL PREPARATION | |
RU2008103617A (en) | BISPHOSPHONIC ACIDS INTENDED FOR TREATMENT AND PREVENTION OF OSTEOPOROSIS | |
UY27533A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING OXIBUTININE | |
BRPI0415953A (en) | oral controlled release dosage formulation, method of treating a disorder, set of controlled release dosage forms and method for administering the formulation | |
RU2008119454A (en) | MEDICINE FOR PROTECTION OF MOTOR NEURON IN PATIENTS WITH LATERAL AMYOTROPHIC SCLEROSIS | |
AR033688A1 (en) | RECONSTITUABLE PARENTERAL COMPOSITION | |
ATE298324T1 (en) | DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
HUP0202781A2 (en) | Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use | |
MEP10808A (en) | Solid drug for oral use | |
BR9709838A (en) | Administration regimen that provides a blood plasma profile of an h +, k + -atpase inhibitor oral pharmaceutical composition and the use of h +, k + -atpase inhibitor and processes to improve the inhibition of gastric acid secretion and the therapeutic effect on treatment of gastrointestinal disorders and to receive an extended plasma profile of an h +, k + -atpase inhibitor | |
AR045289A1 (en) | ORAL DOSAGE FORM OF CONTROLLED RELEASE THAT INCLUDES 4- (2-DI-N-PROPILAMINOETIL) - 2 (3H) -INDOLONE (ROPI-NIROL) AND USE OF SUCH DOSAGE FORM FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
ES2130152T3 (en) | MEDICINES TO TREAT INFLAMMATORY PAIN OR ANALGESIA CONTAINING A NSAID AND RANITIDINE / BISMUTE CITRATE. | |
KR970061244A (en) | Pharmaceutical composition for treating dementia | |
AR046036A1 (en) | RISEDRONATE COMPOSITIONS AND METHODS FOR USE | |
ATE268174T1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING SIBUTRAMIN AND ORLISTAT | |
AR035946A1 (en) | PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES | |
RU2003125274A (en) | APPLICATION OF FLUMAZENIL IN THE PRODUCTION OF MEDICINE FOR TREATMENT OF ALCOHOL DEPENDENCE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |